Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login

The Clinical Cancer Letter - January 2012

publication date: Jan 31, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
  • Regorafenib Trial Meets Primary Endpoint, Improves Overall Survival by 29 Percent
  • Tesetaxel Showed 20 Percent Response in Second-Line Therapy in Phase IIb trial
  • ETP-ALL May Be Linked to Acute Myeloid Leukemia
  • FDA Approvals: Inlyta for Renal Cell Carcinoma
  • NCI-approved trials for the month of January


To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.